The TRINOVA-1 trial: trebananib decreases progression of recurrent ovarian cancer
1. Ovarian cancer patients randomized to receive paclitaxel + trebananib had improved progression-free survival versus paclitaxel + placebo. 2. Patients ...
1. Ovarian cancer patients randomized to receive paclitaxel + trebananib had improved progression-free survival versus paclitaxel + placebo. 2. Patients ...
Image: PD 1. There is no significant difference in treating advanced gastric cancer refractory to chemotherapy with Paclitaxel or Irinotecan. ...
Image: PD 1. Nab-paclitaxel plus gemcitabine improved overall survival, progression-free survival, and response rate compared to gemcitabine alone in advanced ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.